Table 3. Treatment-related adverse events (AEs) at all levels (n=42, phase I/II).

Variables	All grades [%]	Grade 3–4 [%]	Grade 5 [%]
Hematologic
Leukopenia	14 [33]	4 [10]
Neutropenia	16 [38]	6 [14]	1 [2]
Lymphopenia	25 [60]	13 [31]
Anemia	21 [50]	5 [12]
Thrombocytopenia	17 [40]	3 [7]
Nonhematologic
Fatigue	19 [45]	6 [14]
Hypophosphatemia	16 [38]	8 [19]
Nausea/vomiting	16 [38]	1 [2]
Hyperglycemia	15 [36]	4 [10]
Hypomagnesemia	14 [33]	2 [5]
ALT	14 [33]	3 [7]
Hypercholesterolemia	9 [21]	0 [0]
Creatinine	9 [21]	0 [0]
Hypertriglyceridemia	8 [19]	0 [0]
Dyspnea	4 [10]	2 [5]
Infection	6 [14]	2 [5]	1 [2]

ALT, aspartate aminotransferase.